A MULTICENTER, OPEN-LABEL, LONGER-TERM STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY - Longer-term Study of AR101 CODIT™

Start Date12 Feb 2019

Sponsor / Collaborator

Aimmune Therapeutics, Inc.

NCT03736447 / CompletedPhase 3

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.

Start Date27 Dec 2018

Sponsor / Collaborator

Aimmune Therapeutics, Inc.

NCT03703791 / TerminatedPhase 3

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

Start Date24 Oct 2018

Sponsor / Collaborator

Aimmune Therapeutics, Inc.

100 Clinical Results associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

100 Translational Medicine associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

100 Patents (Medical) associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

Literatures (Medical) associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

01 Apr 2024·Pediatric Allergy and Immunology

Current state and advances in desensitization for peanut allergy in pediatric age

Review

Author: Catamerò, Francesco ; Favuzza, Filippo ; Landi, Massimo ; Barberi, Salvatore ; Giovannini, Mattia ; Olcese, Roberta ; Panasiti, Ilenia ; Votto, Martina ; Caminiti, Lucia ; Foti Randazzese, Simone ; De Filippo, Maria

AbstractPeanut allergy affects about 1%–3% of the pediatric population in the world, with an important increase in the last decades. Nowadays, international guidelines recommend the early introduction of peanuts in the infant diet, with poor information about the quantity and the frequency of the intake. Allergen immunotherapy may represent the only therapeutic strategy able to modify the natural history of peanut allergy. In particular, oral immunotherapy showed the most promising results in terms of efficacy, but with significant rates of adverse reactions, mostly gastrointestinal. In 2020, the Food and Drug Administration and the European Medicines Agency approved Palforzia®, an oral drug for patients aged 4–17 years. Several studies are ongoing to improve the tolerability of oral immunotherapy and standardize the desensitization protocols. Sublingual immunotherapy permits to offer much lower doses than oral immunotherapy, but fewer adverse events are shown. Subcutaneous immunotherapy is associated with the greatest systemic adverse effects. Epicutaneous immunotherapy, for which Viaskin® patch was approved, has the highest safety profile. Innovative studies are evaluating the use of biological drugs, such as omalizumab or dupilumab, and probiotics, such as Lactobacillus rhamnosus, in monotherapy or associated with oral immunotherapy. Therapy for peanut allergy is constantly evolving, and new perspectives are ongoing to develop.

image

13 Dec 2023·Cureus

Palforzia for Peanut Allergy: A Narrative Review and Update on a Novel Immunotherapy

Review

Author: Ahmadzadeh, Shahab ; Daniel, Charles P ; Wagner, Maxwell J ; Kaye, Alan D ; Plaisance, Connor J ; Myrcik, Dariusz ; Kelkar, Rucha A ; Shekoohi, Sahar ; Nolen, Alexandra ; Varrassi, Giustino ; Borne, Grant E

With Palforzia appearing as the first oral immunotherapy for patients with peanut allergy, the present investigation aims to summarize recent clinical trials, the mechanism of dosing, and the real-world usage of this novel therapy. Palforzia offers a new avenue for treating the human allergic response in previous immune modulation refractory patients or patients who have undergone immune environment sensitivity testing, which allows for more specialized treatment. Current studies are focusing on certain age groups that have been shown to be more receptive to treatment. Further, studies are tailoring oral immunotherapy treatment alongside other immune modulators to elicit greater targeted immune tolerance. With an increasing prevalence of patient allergies, many questions remain surrounding the optimization of therapies in reaching therapeutic goals. Overall, Palforzia offers a hopeful treatment for peanut-allergic patients to attenuate their immune response while furthering research in related therapies.

24 Oct 2023·NEJM Evidence

Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age

Article

Author: Vereda, Andrea ; Brown, Kari R. ; Du Toit, George ; Irani, Anne-Marie ; Vickery, Brian P. ; Jones, Stacie M. ; Ratnayake, Anoshie ; Tilles, Stephen

BACKGROUND: Peanut allergy is a common childhood allergy, and the only approved treatment for children 4 to 17 years of age is peanut allergen powder-dnfp (PTAH) oral immunotherapy. METHODS: For this phase 3, randomized, double-blind, placebo-controlled trial, we enrolled peanut-allergic children 1 to <4 years of age who experienced dose-limiting symptoms from ≤300 mg peanut protein during a screening double-blind, placebo-controlled food challenge (DBPCFC). Participants received PTAH or placebo, randomized in a 2:1 ratio, for approximately 12 months. At the trial conclusion, all participants underwent an exit BDPCFC. The primary end point was desensitization (i.e., tolerating a ≥600-mg single dose of peanut protein with only mild allergy symptoms). RESULTS: In the PTAH-treated group (n=98), 73.5% of participants tolerated a single dose of ≥600 mg peanut protein at exit DBPCFC compared with 6.3% in the placebo group (n=48). Most participants experienced an adverse event (98.0% of PTAH-treated and 97.9% of placebo-treated participants), which was mild or moderate in grade for 93.2% of participants (92.9% in PTAH-treated and 93.8% in placebo-treated participants). Treatment-related adverse events, which were mild to moderate, were experienced by 75.5% of PTAH-treated and 58.3% of placebo-treated participants. Three treatment-related systemic allergic reactions, none of which were severe or serious in grade, were noted in two PTAH-treated participants (2%). CONCLUSIONS: In peanut-allergic children 1 to <4 years of age treated with PTAH for approximately 12 months, the majority tolerated all peanut protein dose levels assessed. PTAH-treated patients had more treatment-related adverse events, which were mild to moderate severity. (Funded by Aimmune Therapeutics; ClinicalTrials.gov number, NCT03736447.)

News (Medical) associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

30 Jul 2024

·www.businesswire.com

FDA Approves U.S. Pediatric Indication Extension for Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy

BAAR, Switzerland--( BUSINESS WIRE )--Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, today announced that the U.S Food and Drug Administration (FDA) has approved Palforzia ® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of a peanut allergy. This approval expands the January 2020 FDA approval for patients ages 4-17 years. Palforzia ® is to date the first and only approved oral immunotherapy treatment (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. Peanut allergy currently affects approximately 2% of the general population of Western nations 1 , and the prevalence of peanut allergy doubled among children between 2005 and 2015 2 . Compared with other food allergies, peanut allergy is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis 1 . The difficulty in avoiding peanuts, combined with the severity of allergic reactions, shows the need for effective treatment 3 . “ We are delighted that Palforzia ® has received regulatory approval in the U.S. for toddlers as there is a high unmet medical need for this age group and we are confident that this indication extension will alleviate the burden of peanut allergy for younger patients and their families,” says Elena Rizova, MD, PHD, Chief Medical Officer of Stallergenes Greer. The FDA approval in toddlers is based on data from the Phase 3 POSEIDON ( P eanut O ral Immunotherapy S tudy of E arly I ntervention for D esensitizati on ) study that was published in the New England Journal of Medicine Evidence in 2023. The study evaluated the efficacy and safety of Palforzia ® in peanut-allergic children aged 1 to 3 years old, meeting all its primary and secondary efficacy endpoints and demonstrating a favourable safety profile. Stallergenes Greer acquired the rights to Palforzia ® in September 2023. As part of our ongoing commitment to delivering innovative solutions in allergen immunotherapy, our focus in the U.S has been on establishing a specialised Food Allergy business unit and transitioning the product into our AIT portfolio. ABOUT PALFORZIA ® Palforzia ® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients. The treatment is approved for use in patients with a confirmed diagnosis of peanut allergy and in conjunction with a peanut-avoidant diet. Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis. Palforzia ® is approved by the U.S. Food and Drug Administration (FDA) for ages 1-17 years and for ages 4-17 years by the European Medicine Agency (EMA), by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland. Pediatric indication extension submissions are currently under review by the EMA and Swissmedic. ABOUT POSEIDON PHASE 3 STUDY POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, clinicaltrials.gov number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of Palforzia ® in peanut-allergic children aged 1 to 3 years of age in North America and Europe. The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested Palforzia ® to Stallergenes Greer in September 2023. Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge. In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of Palforzia ® or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit double-blind, placebo-controlled food challenge (DBPCFC). ABOUT STALLERGENES GREER INTERNATIONAL AG Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory, food and venom allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com . 1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/ Accessed August 31, 2023 2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023. 3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023. Palforzia®: © 2023, Société des Produits Nestlé S.A. or its affiliates

ImmunotherapyPhase 3Drug ApprovalClinical ResultBiosimilar

16 May 2024

·www.pharmaceutical-technology.com

Food Allergy Awareness Week 2024: How can new treatments target an unmet need?

GlobalData epidemiologists forecast that the food allergy market is forecast to reach $2.7bn by 2030. Credit: Alphavector via Shutterstock. Food Allergy Awareness Week, which runs from 12 to 18 May this year, is drawing attention to the innovations under development for treating food allergies. Earlier this year, a breakthrough in the food allergy space was when Novartis and Roche’s Xolair (omalizumab) won US Food and Drug Administration (FDA) approval. Initially approved for asthma in 2003, its label was expanded, making it the first FDA-approved drug to reduce allergic reactions in people with IgE-mediated food allergies. This classification includes food-based allergens such as peanuts, milk, eggs, wheat, cashew nuts, hazelnut, or walnut. Still, despite the observed efficacy with Xolair, the drug can take a few months to start working properly, highlights Jessica Grossman, CEO of San-Francisco-based allergy company IgGenix. “Xolair is a great step forward for the allergic community. However, there still are some limitations if it takes 16 weeks to work,” she said. IgGenix is developing an IgG4 monoclonal antibody-based therapeutic called IGXN001 specifically for peanut allergies. The candidate is expected to protect against accidental exposure to peanut allergens within days of administration. See Also: Cutting losses in drug manufacturing: A new era in fill-finish technology CinDome Pharma secures $40m to advance gastroparesis treatment The company, which spun out of Stanford University in 2019, closed a $40m Series B financing round in February 2024 to advance IGXN001 to the clinic. The funding round was led by Alexandria Venture Investments and Eli Lilly and Company. Grossman said the company is initiating a Phase I clinical trial later this year following positive preclinical pharmacokinetic (PK) studies: “In our animal studies, the PK of the antibody is modelled to be about 30 days in humans. What we’re hoping that means in humans is that that the antibody will have a relatively long PK or a relatively long concentration time in the blood, longer than Xolair.” The Phase I trial start, targeting late Q3 or Q4 2024, will measure safety as the primary endpoint in otherwise healthy individuals with peanut allergies. The trial design will involve a single-ascending dose across three cohorts and will also examine the blood concentration PK of IGXN001. “We are thinking from some of our modelling [data] that we’ll be able to dose every other month, which would be a big advantage,” added Grossman. There is certainly innovation in the peanut allergy space, highlighted by Intrommune Therapeutics’ desensitisation immunotherapy , which is delivered as toothpaste. The company announced positive results from the Phase I OMEGA clinical trial (NCT04603300) investigating INT301 in November 2023. Data highlighted that 100% of those treated with the toothpaste consistently tolerated the highest dose of the allergen. There are also approved medications to treat peanut allergies, including Palforzia (arachis hypogaea) . Nestlé acquired Palforzia through its $2.6bn takeover of Aimmune Therapeutics in 2020. However, Nestlé shifted the drug to Swiss biopharma Stallergenes Greer in September 2023, following a “ slower than expected adoption by patients and healthcare professionals”. Palforzia needs to be taken daily and carries a warning for anaphylaxis on its label. Grossman commented on oral medications in the young patient population: “Generally, oral immunotherapy isn’t for them. There’s definitely an unmet need in the young adult population.” DBV Technologies , which is developing an allergen patch called Viaskin, has faced multiple challenges in getting it to the market in the past few years, following a clinical hold and the FDA requesting additional data in April 2023. According to a report on GlobalData’s Pharma Intelligence Center, the food allergy market was valued at $213.9m in 2020 globally and is forecast to reach $2.7bn by 2030, growing at a compound annual growth rate (CAGR) of 28.8%. In the eight major markets (UK, US, Germany, France, Italy, Spain, Australia, and Canada), GlobalData epidemiologists forecast that there will be more than seven million peanut allergy cases in 2027.

Phase 1Drug ApprovalImmunotherapyClinical ResultAcquisition

16 Feb 2024

·www.fiercepharma.com

FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies

Novartis and Roche's Xolair has been approved by the FDA to prevent severe allergic reactions to common foods such as peanuts, tree nuts, milk, eggs and wheat. People with food allergies finally have a medicine that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. The FDA has blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur with accidental exposure to certain foods. The drug is approved for people ages 1 year and older with certain allergies. The therapy is for people with IgE-mediated food allergies, a classification that includes 160 foods, the most common of which are peanuts, milk, eggs, wheat, soy and tree nuts. Xolair is not designed to allow patients to freely eat these foods. It just helps them avoid severe reactions, including anaphylaxis, a life-threatening condition that can happen immediately as the immune system releases chemicals that can cause the body to go into shock. There are 3.4 million children in U.S. that have food allergies and more than 40% of them have had at least one severe reaction, according to Roche subsidiary Genentech. Food reactions cause approximately 30,000 emergency room visits each year in the U.S. The approval came just two months after the FDA accepted the companies’ supplemental biologics license application in this indication. After injections of Xolair every two to four weeks—with intervals determined by body weight and serum immunoglobulin E (IgE) level—patients would be protected. Backing the green light are results of a phase 3 trial, which was co-sponsored by the U.S. National Institutes of Health. The phase 3 OUtMATCH study showed that Xolair significantly increased the amount of peanut (primary endpoint) and milk, egg and cashew (secondary endpoints) it took to cause an allergic reaction compared to placebo. Study results showed 68% of patients treated with Xolair for 16 to 20 weeks tolerated at least 600 mg of peanut protein without moderate to severe allergic symptoms, compared to 5% of those treated with placebo. This amount is equivalent to approximately two and a half peanuts, or half a teaspoon of regular peanut butter. Xolair was first approved by the FDA in 2003 for asthma. The drug generated $3.9 billion in sales last year. Xolair works by inhibiting IgE antibodies, which cause chemical reactions that produce inflammation seen in allergy and asthma attacks. In 2018, the FDA granted breakthrough designation for Xolair as a treatment for food allergies. “Many people with food allergies and their loved ones live in constant fear of accidentally coming into contact with the food they are allergic to and the life-threatening allergic reaction,” Reshema Kemps-Polanco, Novartis U.S. chief commercial officer, said in a release. “Today’s approval of Xolair represents a paradigm shift in the way food allergies can be managed.” In September of last year, Nestle sold its peanut allergy drug Palforzia to Stallergenes Greer for an undisclosed sum. In 2020, Palforzia was the first peanut allergy drug approved by the FDA, but its sales never indicated it could reach Evaluate Pharma’s projection of $1.28 billion by 2024. Nestle acquired Palforzia in a $2.1 billion buyout of Aimmune Therapeutics.

Clinical ResultDrug ApprovalPhase 3AcquisitionBreakthrough Therapy

100 Deals associated with Peanut (Arachis hypogaea) Allergen Powder-dnfp

External Link

KEGG	Wiki	ATC	Drug Bank
-	Peanut (Arachis hypogaea) Allergen Powder-dnfp	V01AA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peanut Hypersensitivity	US	Aimmune Therapeutics, Inc.	31 Jan 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peanut Hypersensitivity	Phase 3	GB	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	CA	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	IT	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	SE	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	NL	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	ES	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	DE	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 3	IE	Aimmune Therapeutics, Inc.	22 Dec 2015
Peanut Hypersensitivity	Phase 1	DK	Aimmune Therapeutics, Inc.	22 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03682770 (CTgov)	Phase 2	Peanut Hypersensitivity	148	Placebo+AR101 (AR101 Up-dosing Period: Placebo + AR101)	lmlyamkbkp(mgaqozwlfs) = wafubgcfyq cxqcbcsmmg (pnnrdxvxml, fsxzeivkmu - zpoqmfziwj) View more	-	07 Feb 2024
				Dupilumab+AR101 (AR101 Up-dosing Period: Dupilumab + AR101)	lmlyamkbkp(mgaqozwlfs) = cgvgeajbry cxqcbcsmmg (pnnrdxvxml, ocuiigdzmq - cxivkjlxxu) View more
NCT03736447 (POSEIDON, CTgov)	Phase 3	Peanut Hypersensitivity	146	AR101 (AR101)	szsfabiwgy(alqkvdocse) = tmtmobzswp yynbdrigal (sezpodajov, tkfnwubaqr - kryzqluaur) View more	-	02 Mar 2023
				Placebo+AR101 (Placebo)	szsfabiwgy(alqkvdocse) = rfhnwehtnv yynbdrigal (sezpodajov, ufwbmdstuo - ddfryacdgo) View more
NCT03736447 (POSEIDON, Biospace) Manual	Phase 3	Peanut Hypersensitivity	-	PALFORZIA	(puszicyegc) = skaphwqmdm mzwibadaqe (ruuhgwpjzp ) View more	Positive	10 Nov 2022
				Placebo	(puszicyegc) = ozzvmmdfdt mzwibadaqe (ruuhgwpjzp ) View more
NCT02635776 (PALISADE, CTgov)	Phase 3	Peanut Hypersensitivity	555	peanut protein+AR101 (AR101)	erhvborwbh(glleoujgwy) = kkewfxbryh nbehormffb (bzngyswzyj, wjytifyjmd - duszgnkgmg) View more	-	17 Mar 2022
				Placebo (Placebo)	erhvborwbh(glleoujgwy) = vagnwxazlc nbehormffb (bzngyswzyj, ioyarvjoes - kulgehgptv) View more
NCT02198664 (CTgov)	Phase 2	Peanut Hypersensitivity	47	AR101 - Peanut protein capsule (ARC001 Placebo Group)	tbukezlega(bmeftwvhnm) = xrxerzbwww oqnqjewowl (kbvozdezrr, xmcojiolte - zvibdbgosb) View more	-	09 Nov 2021
				AR101 - Peanut protein capsule (ARC001 AR101 Group)	tbukezlega(bmeftwvhnm) = ddugshzugv oqnqjewowl (kbvozdezrr, mpmeaeugbe - cismgwvrvg) View more
NCT03337542 (CTgov)	Phase 3	Peanut Hypersensitivity	243	AR101	esayarfgby(qvohhidjtk) = ombfdbnawg tvjnlulrtf (gzkucbnbkl, gadtqfkbzq - rqqfxkyqku) View more	-	02 Nov 2021
NCT01987817 (ARC001, CTgov)	Phase 2	Peanut Hypersensitivity	56	AR101 powder provided in capsules (AR101 Powder Provided in Capsules)	jpqmviupfa(vuyzygoskv) = upiuhsvyna pomjyljehb (ftgcazinnx, honpstvxkr - ipgriqgcbo) View more	-	02 Nov 2021
				Placebo powder provided in capsules (Placebo Powder Provided in Capsules)	jpqmviupfa(vuyzygoskv) = iorvwhdxin pomjyljehb (ftgcazinnx, zcszstjebb - ycokyihtpg) View more
NCT03126227 (RAMSES, CTgov)	Phase 3	Peanut Hypersensitivity	506	AR101 (AR101 Powder Provided in Capsules)	tkdbjvssoe(ieaikqvljj) = bsnysdivks tanycwserk (dcypdbqafz, ftanqjzugx - rovkowyqvd) View more	-	02 Nov 2021
				Placebo (Placebo Powder)	tkdbjvssoe(ieaikqvljj) = cgkcqnfmiw tanycwserk (dcypdbqafz, nhqczwbfqr - xfrzctheik) View more
NCT03201003 (ARTEMIS, CTgov)	Phase 3	Peanut Hypersensitivity	175	AR101 powder provided in capsules & sachets (AR101)	ulgqqikjbh(kwceydkamm) = hlugqoqise lleionagav (uatexwviwx, vdinibjhoo - scjfacznnu) View more	-	03 Aug 2021
				Placebo powder provided in capsules & sachets (Placebo)	ulgqqikjbh(kwceydkamm) = lqtqdxthvl lleionagav (uatexwviwx, jyvysorrjo - dpczlupwcf) View more
AAAAI2021	Not Applicable	-	57	Palforzia	bsjmyfpuzq(drsuiwntfr) = ipmsyiemfm mckdrubyqk (eadhhjzcno ) View more	-	01 Feb 2021
				Palforzia	xxahjyrobq(mezgruvhyr) = utwudipify rldczronyo (fzfmwbubxp )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Peanut (Arachis hypogaea) Allergen Powder-dnfp

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation